News
Business Results Q3 of 2016
Sales and operating margins continue to improve from Q2 to Q3 of FY 2016. Strong revenue growth reported in the third quarter of FY 2016 over the previous quarter. Sales increased from $956k to $1,414k from Q2 2016 to Q3 2016 respectively, an over 47% increase. The increase was due to organic growth in the sales from our subsidiary Sky Pharm SA. Gross operating margins also improved from Q2 2016 to Q3 2016. Cosmos Holdings was successful in raising ...
Cosmos Holdings enters into a Memorandum of Understanding to acquire Medihelm Pharmaceutical Wholesellers SA
On October 19, 2016, the Cosmos Holdings entered into a Memorandum of Understanding with Medihelm Pharmaceutical Wholesellers SA and each of Konstantinos Metsovitis and Eleni Metsoviti. The Medihelm MOU provides that the Company intends to acquire all of the issued and outstanding shares of Medihlem from Konstantinos Metsovitis in exchange for 200,000 shares of the Company’s common stock. Upon the closing of the transactions, Eleni Metsoviti shall be appointed as a member of the Board of Directors of ...
Cosmos Holdings enters into a Memorandum of Understanding to acquire Decahedron LTD
On October 18, 2016, Cosmos Holdings Inc., a Nevada corporation entered into a Memorandum of Understanding with Decahedron LTD and Decahedron’s sole shareholder Nikolaos Lazarou. The Decahedron MOU provides that the Cosmos Holdings intends to acquire all of the issued and outstanding shares of Decahedron from Nikolaos Lazarou. In exchange for the shares of Decahedron, the Company will issue to Nikolaos Lazarou 1,700,000 shares of the Cosmos Holding’s common stock. Following the closing of the transaction, Nikolaos ...
Cosmos Holdings enters into an Intellectual Property Sale Agreement for a formula related to prostate health
On October 1, 2016, Cosmos Holdings Inc., entered into an Intellectual Property Sale Agreement with Anastasios Tsekas and Olga Parthenea Georgatsou for the purchase of certain intellectual property rights relating to proprietary pharmaceutical formulas and any related technical information arising or related Intellectual property. The formula is related to a possible prostate health improvement and cure including prostate gland enlargement, prostate infections, prostate cancer, and other urinary problems. Cosmos Holdings is in the process of locating a specialized ...
Increased Loan Facility to $1,532,974 as a result SYNTHESIS PEER-TO-PEER INCOME FUND advancing $240,251 to Sky Pharm
On September 13, 2016, Sky Pharm S.A., a wholly owned subsidiary of Cosmos Holdings Inc., entered into a First Deed of Amendment to Loan Facility Agreement dated as of August 4, 2016 and guaranteed by Grigorios Siokas, with Synthesis Peer-To Peer-Income Fund. The Loan Facility provided Sky Pharm with a credit facility of up to $1,292,769. The Amendment increased the Loan Facility to $1,532,974 as a result of the Lender having advanced $240,251 to Sky Pharm. The ...
Photo
Steve Carr Managing Director

Join our mailing list to stay up to date.

Cosmos-logo